Your session is about to expire
← Back to Search
Other
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients (OKN-007 Trial)
Phase 1
Waitlist Available
Led By James Battiste, MD, PhD
Research Sponsored by Oblato, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug on patients with brain cancer that has come back after standard treatments. The goal is to see if this new drug can help treat their cancer.
Eligible Conditions
- Brain Tumor
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Adverse events per patient
Secondary study objectives
6 month progression-free survival
PK level in participants
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: All patientsExperimental Treatment1 Intervention
All participants enrolled in this study
Find a Location
Who is running the clinical trial?
Oblato, Inc.Lead Sponsor
4 Previous Clinical Trials
73 Total Patients Enrolled
James Battiste, MD, PhDPrincipal Investigator• Oklahoma University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You've had radiation treatment in the past.You cannot have any other active cancer, except for treated skin cancer. If you had another type of cancer in the past, you can participate if you have been cancer-free for more than 2 years.You have taken a medication that is not approved by regulatory authorities within the last 28 days.You have to fully recover from any previous treatment and wait at least 28 days before starting this clinical trial.
Research Study Groups:
This trial has the following groups:- Group 1: All patients
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.